Global Payments Inc. $GPN Shares Sold by Assenagon Asset Management S.A.
📉 Assenagon sold 1M shares, dropping stake to $13.54M value.
📈 Pzena bought 500k shares, holding 11.4M worth $883.11M.
📈 Westpac added 56k shares, expanding position by 5,795%.
📉 Weiss downgraded stock to 'sell' and Argus cut target to $95.
💰 Q1 revenue surged 63% YoY; EPS beat at $2.96.
📉 Assenagon Asset Management S.A. reduced its Global Payments stake by 83.3% in Q1, selling 1,006,042 shares to hold a remaining value of $13.54 million.
📈 Pzena Investment Management LLC increased its holdings by 4.6% in Q4, purchasing an additional 500,887 shares to own 11.4 million total shares valued at $883.11 million.
📈 Westpac Banking Corp expanded its position by 5,795.1% in the 4th quarter, buying 56,212 additional shares worth $4.43 million.
📉 Weiss Ratings downgraded Global Payments from a 'hold (c-)' to a 'sell (d)' rating on May 11th.
📉 Argus lowered its price target for the stock from $100.00 to $95.00 in a report dated May 8th.
📈 Global Payments reported Q1 revenue of $2.86 billion, representing a 63.1% year-over-year increase against consensus estimates.
💰 The company beat quarterly earnings expectations with $2.96 EPS compared to the analyst consensus of $2.82.
📊 Analysts have set a consensus price target of $83.87 with a 'Hold' rating, though Morgan Stanley initiated coverage at $65.
💸 Global Payments paid a quarterly dividend of $0.25 on June 26th, resulting in an annualized yield of 1.4%.
⚠️ The company currently has a negative net margin of -7.99% and a debt-to-equity ratio of 0.86.
- Revenue hit $2.86 billion, up 63.1% year-over-year.
- EPS of $2.96 beat estimates by $0.14 per share.
- Pzena added 500,887 shares, increasing stake by 4.6%.
- Westpac ownership surged 5,795.1% in the fourth quarter.
- Moore Capital grew stake 13.3% with 27,200 new shares.
- Invenomic expanded position 11.1% by buying 68,071 shares.
- Full-year 2026 EPS guidance set at $13.80-$14.00.
- Citigroup maintains buy rating despite lowering price target.
- Weiss downgraded to sell on May 11th.
- Argus lowered price target from $100.00 to $95.00.
- BNP Paribas cut objective to $60.00 and rated underperform.
- Negative net margin of -7.99% despite revenue growth.
- Negative P/E ratio of -34.28 indicates earnings losses.
- Dividend payout ratio is -49.02%, funded by reserves.
- Morgan Stanley $65.00 target below current ~$70 price.
- Global Payments reported revenue of $2.86 billion for the quarter, which represents a significant 63.1% year-over-year increase.
- The company beat analyst earnings estimates by $0.14 per share, reporting $2.96 EPS versus the consensus of $2.82.
- Pzena Investment Management LLC increased its stake by 4.6% in Q4, adding 500,887 shares to its position.
- Westpac Banking Corp dramatically increased its ownership percentage by 5,795.1% in the fourth quarter.
- Moore Capital Management LP grew its stake by 13.3% in the third quarter, purchasing an additional 27,200 shares.
- Invenomic Capital Management LP expanded its position by 11.1% in Q3, acquiring 68,071 additional shares.
- The company has set full-year 2026 guidance of $13.80-$14.00 EPS, which aligns closely with the analyst consensus target of $13.86.
- Citigroup maintains a 'buy' rating for the stock despite lowering its price target to $90.
- Weiss Ratings downgraded Global Payments from a 'hold (c-)' to a 'sell (d)' rating on May 11th.
- Argus lowered its price target for the stock from $100.00 to $95.00 in late May.
- BNP Paribas Exane decreased its price objective from $64.00 to $60.00 and assigned an 'underperform' rating.
- The company reported a negative net margin of -7.99% for the quarter despite strong revenue growth.
- Global Payments has a negative P/E ratio of -34.28, indicating recent earnings volatility or losses affecting valuation multiples.
- The stock's dividend payout ratio is currently -49.02%, suggesting the company is paying dividends from cash reserves rather than current earnings.
- Morgan Stanley initiated coverage with an 'equal weight' rating and a $65.00 price objective, which is below the current trading price of roughly $70.